
Search documents
长安汽车(000625):深蓝及阿维塔销量同比较高增长,新车即将上市
东方证券· 2025-04-10 09:59
盈利预测与投资建议 ⚫ 预测 2024-2026 年归母净利润 59.47、82.68、101.25 亿元,可比公司 25 年平均 PE 估值 21 倍,目标价 17.43 元,维持买入评级。 风险提示 长安福特销量低于预期、长安马自达销量低于预期、长安自主品牌销量低于预期、行业 价格战影响盈利。 深蓝及阿维塔销量同比较高增长,新车即 将上市 核心观点 公司主要财务信息 | | 2022A | 2023A | 2024E | 2025E | 2026E | | --- | --- | --- | --- | --- | --- | | 营业收入(百万元) | 121,253 | 151,298 | 174,823 | 194,292 | 213,009 | | 同比增长 (%) | 15.3% | 24.8% | 15.5% | 11.1% | 9.6% | | 营业利润(百万元) | 7,634 | 10,447 | 6,252 | 8,717 | 10,681 | | 同比增长 (%) | 104.6% | 36.9% | -40.2% | 39.4% | 22.5% | | 归属母公司净利润(百万元) ...
泰恩康(301263):首次覆盖报告:拐点将至,CKBA打开成长空间
东方证券· 2025-04-10 09:34
泰恩康 301263.SZ 公司研究 | 首次报告 拐点将至,CKBA 打开成长空间 ——泰恩康首次覆盖报告 核心观点 盈利预测与投资建议 ⚫ 公司核心业务或重要产品未来 1-2 年处于快速进展时期,我们预测公司 2024-2026 年每股收益分别为 0.26、0.39 和 0.62 元。根据可比公司 2025 年平均估值,给予公 司当年 54 倍市盈率,对应目标价 21.06 元,首次给予"增持"评级。 风险提示 研发进展不及预期风险;新产品放量低预期风险;市场竞争加剧风险;毛利率提升不及 预期风险。 公司主要财务信息 | | 2022A | 2023A | 2024E | 2025E | 2026E | | --- | --- | --- | --- | --- | --- | | 营业收入(百万元) | 783 | 761 | 757 | 951 | 1,214 | | 同比增长 (%) | 19.9% | -2.9% | -0.5% | 25.7% | 27.6% | | 营业利润(百万元) | 209 | 191 | 147 | 216 | 340 | | 同比增长 (%) | 51.0% | -8 ...
吉比特(603444):新游陆续上线贡献增量
东方证券· 2025-04-10 09:04
吉比特 603444.SH 公司研究 | 年报点评 | | 增持 (维持) | | --- | --- | | 股价(2025年04月08日) | 204.8 元 | | 目标价格 | 207.90 元 | | 52 周最高价/最低价 | 265.93/148.25 元 | | 总股本/流通 A 股(万股) | 7,204/7,204 | | A 股市值(百万元) | 14,754 | | 国家/地区 | 中国 | | 行业 | 传媒 | | 报告发布日期 | 2025 年 04 月 10 日 | | | 1 周 | 1 月 | 3 月 | 12 月 | | --- | --- | --- | --- | --- | | 绝对表现% | -9.3 | -10.18 | -0.24 | 18.78 | | 相对表现% | -3.21 | -2.74 | 3.41 | 15.55 | | 沪深 300% | -6.09 | -7.44 | -3.65 | 3.23 | | 项雯倩 | 021-63325888*6128 | | --- | --- | | 李雨琪 | xiangwenqian@orientsec. ...
云南白药2024年报点评:业绩强劲增长,业务结构优化
东方证券· 2025-04-10 05:23
公司主要财务信息 | | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业收入(百万元) | 39,111 | 40,033 | 42,417 | 44,281 | 46,777 | | 同比增长 (%) | 7.2% | 2.4% | 6.0% | 4.4% | 5.6% | | 营业利润(百万元) | 4,831 | 5,712 | 6,050 | 6,653 | 7,328 | | 同比增长 (%) | 43.3% | 18.2% | 5.9% | 10.0% | 10.1% | | 归属母公司净利润(百万元) | 4,094 | 4,749 | 5,103 | 5,594 | 6,140 | | 同比增长 (%) | 36.4% | 16.0% | 7.5% | 9.6% | 9.8% | | 每股收益(元) | 2.29 | 2.66 | 2.86 | 3.14 | 3.44 | | 毛利率(%) | 26.5% | 27.9% | 28.9% | 29.4% | 29.8% | | ...
云南白药(000538):2024年报点评:业绩强劲增长,业务结构优化
东方证券· 2025-04-10 03:23
业绩强劲增长,业务结构优化 ——云南白药 2024 年报点评 核心观点 盈利预测与投资建议 ⚫ 考虑到公司提质增效的效果显著,我们下调销售费用率预期,预测公司 2025-2027 年每股收益分别为 2.86、3.14、3.44 元(原预测值 2025-2026 年每股收益分别为 2.81/3.11 元),参考可比公司平均市盈率,我们给予公司 2025 年 22 倍 PE 估值, 对应目标价 62.92 元,维持"买入"评级。 风险提示 ⚫ 药品销售不达预期、创新药研发不达预期等。 公司主要财务信息 | | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业收入(百万元) | 39,111 | 40,033 | 42,417 | 44,281 | 46,777 | | 同比增长 (%) | 7.2% | 2.4% | 6.0% | 4.4% | 5.6% | | 营业利润(百万元) | 4,831 | 5,712 | 6,050 | 6,653 | 7,328 | | 同比增长 (%) | 43.3 ...
因子选股系列之一一二:ADWM:基于门控机制的自适应动态因子加权模型
东方证券· 2025-04-10 02:46
ADWM:基于门控机制的自适应动态因子 加权模型 ——因子选股系列之一一二 研究结论 自适应动态因子加权模型 金融工程 | 专题报告 为了克服市场状态市场风格发生突变时,短周期加权模型很有可能学习到错误的规律从 而造成巨大的回撤,我们设计了一套端到端因子生成和因子加权模型。该模型通过学习 市场上长期历史数据既捕捉 alpha 信息,又根据市场状态和个股属性信息学习 alpha 因子 的时变规律来对 alpha 因子进行加权,该模型框架由两部分组成: 各模型因子对比 根据输入的不同和加权方式的不同,我们提出了五个模型并进行对比,得到以下结论: 因子在各宽基指数上表现 风险提示 报告发布日期 2025 年 04 月 10 日 | 杨怡玲 | yangyiling@orientsec.com.cn | | --- | --- | | | 执业证书编号:S0860523040002 | | 陶文启 | taowenqi@orientsec.com.cn | | | 执业证书编号:S0860524080003 | ABCM:基于神经网络的alpha因子和beta 因子协同挖掘模型:——因子选股系列之 一一〇 2024- ...
美团-W:美团24Q4点评:核心主业好于预期,海外加大投入-20250410
东方证券· 2025-04-10 01:23
美团-W 03690.HK 公司研究 | 季报点评 美团 24Q4 点评:核心主业好于预期,海 外加大投入 核心观点 1)外卖:单量高个位数增长,单均 OP 同比提升。运营端,我们测算 24Q4 外卖订 单同增高个位数。需求侧,"省"的用户心智进一步强化。供给侧,拼好饭激发更 多消费需求并提高了用户消费频次,品牌卫星店帮助品牌餐饮商家有效实现低成本 扩张,以及神抢手更好满足消费者对品质外卖需求。收入端,宏观因素影响下 24Q4AOV 同比下降、但跌幅环比有所收窄,配送收入、广告变现效率提升,一定 程度上抵消 AOV 下滑对收入的不利影响。利润端,我们判断拼好饭单量占比提升, 低价订单 UE 持续改善,以及货币化率提升,综合作用下单均 OP 同比继续改善、 环比有所下降。展望,宏观经济持续对外卖单量和 AOV 造成影响,同时外卖商户对 营销 ROI 转化效率的看重或使得部分线下预算转投线上渠道,带来广告收入增长的 结构性机会。此外,骑手社保方面,将在二季度开始试点社保方案,持续关注公司 运营提效对相关成本的抵消影响。 2)闪购:全年实现盈利。运营端,我们测算 24Q4 闪购订单同增约 25%。需求 侧,即时零售 ...
美团-W(03690):24Q4点评:核心主业好于预期,海外加大投入
东方证券· 2025-04-09 14:28
Investment Rating - The investment rating for Meituan is "Buy" (maintained) with a target price of 178.12 HKD [5][12]. Core Insights - The overall performance of Meituan in Q4 2024 exceeded expectations, with revenue reaching 885 billion CNY, a year-on-year increase of 20% [9]. - The core local business showed resilience, with revenue of 656 billion CNY in Q4 2024, up 19% year-on-year [9]. - New business segments, particularly in overseas markets, are seeing positive developments with a revenue increase of 24% year-on-year [10]. Summary by Sections Delivery Business - In Q4 2024, the delivery orders grew in the high single digits, with an improvement in average order profit year-on-year. The average order value (AOV) decreased year-on-year but the decline was less severe compared to the previous quarter [2]. - The operational efficiency is expected to improve with the trial of social security plans for delivery riders starting in Q2 [2]. Flash Purchase - The flash purchase segment achieved profitability in 2024, with a 25% year-on-year increase in orders. The growth is driven by increased convenience in instant retail and expansion in lower-tier markets [3]. In-store and Travel - The in-store and travel segment saw over 65% year-on-year growth in order volume in 2024, with record highs in annual transaction users and active merchants [4]. - The revenue growth slightly outpaced the gross transaction value (GTV) growth, indicating effective marketing strategies [4]. Financial Projections - Revenue for 2024 is projected at 337.59 billion CNY, with a year-on-year growth of 21.99%. The adjusted net profit is expected to reach 35.81 billion CNY, reflecting a significant recovery from previous losses [12][14]. - The company’s valuation is estimated at 10,882 billion HKD, with specific valuations for different segments: 3.5x PS for delivery, 13.2x PE for in-store and travel, and 0.6x P/GMV for new businesses [15].
吉利汽车:新车上市促进3月销量实现较高增长-20250409
东方证券· 2025-04-09 14:28
Investment Rating - The report maintains a "Buy" rating for Geely Automobile [5] Core Views - Geely's March sales showed significant growth, with total sales reaching 232,200 units, a year-on-year increase of 53.9% and a month-on-month increase of 13.3%. The sales of new energy vehicles reached 119,700 units, up 167.2% year-on-year [7] - The report forecasts EPS for 2025-2027 to be 1.27, 1.50, and 1.84 RMB respectively, maintaining a target price of 20.55 HKD based on a PE ratio of 15 times [2] - The report highlights the launch of new models and the advancement in intelligent driving technology, which are expected to enhance sales performance [7] Financial Forecasts - Revenue is projected to grow from 179,204 million RMB in 2023 to 414,141 million RMB in 2027, with a compound annual growth rate (CAGR) of 16.5% [4] - Operating profit is expected to increase from 3,806 million RMB in 2023 to 17,395 million RMB in 2027, reflecting a CAGR of 23.3% [4] - Net profit attributable to the parent company is forecasted to rise from 5,308 million RMB in 2023 to 18,526 million RMB in 2027, with a notable increase of 213.3% in 2024 [4] Sales Performance - Geely's brand sales in March reached 191,500 units, a year-on-year increase of 62.0%, with the Galaxy series achieving a remarkable 290.3% growth [7] - The report indicates that Geely's sales growth is expected to outperform the industry average, which saw a 10% increase in March [7] Model Launches and Innovations - The report details the launch of several new models, including the Galaxy series and the Zeekr brand, which are expected to contribute significantly to sales in 2025 [7] - The introduction of the L3 level intelligent driving technology is highlighted as a strategic move to enhance Geely's competitive edge in the market [7]
力诺药包(301188):动态更新:股权激励指引方向,持续回购增强信心
东方证券· 2025-04-09 14:05
力诺药包 301188.SZ 公司研究 | 动态跟踪 股价(2025年04月08日) 16.31 元 目标价格 18.60 元 52 周最高价/最低价 19.28/10.78 元 总股本/流通 A 股(万股) 23,245/23,245 A 股市值(百万元) 3,791 国家/地区 中国 行业 建材 报告发布日期 2025 年 04 月 09 日 买入 (维持) | | 1 周 | 1 月 | 3 月 | 12 月 | | --- | --- | --- | --- | --- | | 绝对表现 | -10.33 | -2.68 | 7.09 | -2.3 | | 相对表现 | -4.24 | 4.76 | 10.74 | -5.53 | | 沪深 300 | -6.09 | -7.44 | -3.65 | 3.23 | 冯孟乾 fengmengqian@orientsec.com.cn 执业证书编号:S0860523070003 股权激励指引方向,持续回购增强信心 ——力诺药包动态更新 核心观点 力诺药包动态跟踪 —— 股权激励指引方向,持续回购增强信心 盈利预测与投资建议 ⚫ 调整公司 2024-2026 ...